Guerrilla RF, Inc. (GUER)
OTCMKTS · Delayed Price · Currency is USD
1.100
-0.050 (-4.35%)
Aug 1, 2025, 2:54 PM EDT
CTI BioPharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2020 |
| 19.4 | 20.12 | 15.08 | 11.6 | 10.48 | 8.09 | Upgrade | |
Revenue Growth (YoY) | 14.52% | 33.41% | 29.98% | 10.70% | 29.55% | 15.13% | Upgrade |
Cost of Revenue | 7.13 | 7.3 | 6.47 | 4.84 | 4.34 | 2.91 | Upgrade |
Gross Profit | 12.26 | 12.81 | 8.6 | 6.77 | 6.14 | 5.18 | Upgrade |
Selling, General & Admin | 12.4 | 11.87 | 11.25 | 9.75 | 5.22 | 3.13 | Upgrade |
Research & Development | 9.95 | 9.71 | 10.28 | 8.11 | 4.59 | 3.59 | Upgrade |
Operating Expenses | 22.35 | 21.58 | 21.53 | 17.87 | 9.81 | 6.72 | Upgrade |
Operating Income | -10.09 | -8.76 | -12.92 | -11.1 | -3.67 | -1.54 | Upgrade |
Interest Expense | -1.79 | -3.27 | -2.9 | -0.87 | -0.55 | -0.47 | Upgrade |
Interest & Investment Income | 0.23 | 0.16 | - | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | 2.25 | 2.64 | -0.14 | -0.03 | 0.01 | - | Upgrade |
EBT Excluding Unusual Items | -9.4 | -9.23 | -15.97 | -12.01 | -4.21 | -2.01 | Upgrade |
Asset Writedown | - | - | - | -0.02 | - | - | Upgrade |
Other Unusual Items | -1.52 | -1.52 | - | - | 1.37 | - | Upgrade |
Pretax Income | -10.92 | -10.75 | -15.97 | -12.03 | -2.84 | -2.01 | Upgrade |
Net Income | -10.92 | -10.75 | -15.97 | -12.03 | -2.84 | -2.01 | Upgrade |
Net Income to Common | -10.92 | -10.75 | -15.97 | -12.03 | -2.84 | -2.01 | Upgrade |
Shares Outstanding (Basic) | 10 | 10 | 7 | 6 | 2 | 0 | Upgrade |
Shares Outstanding (Diluted) | 10 | 10 | 7 | 6 | 2 | 0 | Upgrade |
Shares Change (YoY) | 36.13% | 35.11% | 28.02% | 184.53% | 416.83% | 3.61% | Upgrade |
EPS (Basic) | -1.07 | -1.12 | -2.25 | -2.17 | -1.45 | -5.33 | Upgrade |
EPS (Diluted) | -1.07 | -1.12 | -2.25 | -2.17 | -1.45 | -5.33 | Upgrade |
Free Cash Flow | -8.48 | -7.03 | -13.56 | -9.8 | -5.21 | -2.26 | Upgrade |
Free Cash Flow Per Share | -0.83 | -0.73 | -1.91 | -1.76 | -2.67 | -5.99 | Upgrade |
Gross Margin | 63.22% | 63.70% | 57.07% | 58.32% | 58.59% | 64.01% | Upgrade |
Operating Margin | -52.00% | -43.56% | -85.72% | -95.69% | -35.02% | -19.06% | Upgrade |
Profit Margin | -56.31% | -53.45% | -105.89% | -103.67% | -27.07% | -24.87% | Upgrade |
Free Cash Flow Margin | -43.70% | -34.97% | -89.91% | -84.46% | -49.74% | -27.97% | Upgrade |
EBITDA | -8.64 | -7.25 | -11.33 | -9.74 | -3.3 | -1.28 | Upgrade |
EBITDA Margin | -44.52% | -36.04% | -75.15% | -83.99% | -31.47% | -15.77% | Upgrade |
D&A For EBITDA | 1.45 | 1.51 | 1.59 | 1.36 | 0.37 | 0.27 | Upgrade |
EBIT | -10.09 | -8.76 | -12.92 | -11.1 | -3.67 | -1.54 | Upgrade |
EBIT Margin | -52.00% | -43.56% | -85.72% | -95.69% | -35.02% | -19.06% | Upgrade |
Revenue as Reported | 19.4 | 20.12 | 15.08 | 11.6 | 10.48 | 8.09 | Upgrade |
Advertising Expenses | - | 0.01 | 0.02 | 0.04 | 0.02 | 0.04 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.